Tissue repair, wound healing, musculoskeletal recovery, angiogenesis
Wolverine (BPC-157 + TB-500)
A research blend combining BPC-157 and TB-500, primarily investigated through separate preclinical literature involving tissue repair, cell migration, angiogenesis, wound healing, and musculoskeletal recovery.
Administration Reference
Subcutaneous
Formulation & Context
Premixed research blends commonly combine BPC-157 and TB-500 in approximately equal amounts
Dose Information
500 mcg–1 mg total combined peptide
Frequency
Daily
Duration / Cycle
4–8 weeks
Off-Cycle
4 weeks minimum
Timing
Any time
Storage Guidance
Refrigerate after reconstitution and use within approximately 30 days, Freeze for lyophilized powder form
Supplies
Affiliate disclosure: We may earn a commission if you purchase through these links.
Listings are not a required kit or confirmation of suitability for a particular peptide, formulation, or route. Check the product specifications and intended use.
Syringes & transfer supplies
EasyTouch U-100 Insulin Syringes (31G 0.5cc 5/16″) – 100ct.U-100 Insulin Syringes (31G 0.5cc 5/16") – 100ctInsulin syringes – Polybag, 50 Unit Capacity, 5/16” Needle Length, Bold Markings for Accurate Dosing, Disposable, Box of 100View at AMAZON →
Protective supplies & disposal
MED PRIDE Sterile Alcohol Prep Pads1 BOX OF 200INDIVIDUALLY WRAPPED ISOPROPYL ALCOHOL WIPES, PACK OF 1 BOX OF 200, MEDIUM SIZE PREP PADSView at AMAZON →
Inspire Black Nitrile Gloves HEAVY DUTY 6 Mil100ctView at AMAZON →
Square Sharps Container, 2 QuartQTY 1View at AMAZON →
Commonly Reported Uses
Tendon and ligament recovery; muscle injury research; connective-tissue repair; wound healing; joint-related recovery; post-injury rehabilitation; inflammation and regenerative research. These are not established clinical indications.
Commonly Reported Indicators
Commonly reported observations include reduced localized discomfort, improved mobility or range of motion, improved activity tolerance, and perceived faster recovery. No validated human response markers exist for the combination.
Mechanism Overview
The proposed rationale combines two different repair pathways. BPC-157 has demonstrated VEGFR2/Akt/eNOS-related angiogenic activity and effects on cell migration in preclinical research. The actin-binding region associated with TB-500 promotes endothelial-cell migration, angiogenesis, and wound repair. Whether combining the two produces additive or synergistic effects has not been established in controlled studies.
Safety
Safety Considerations
The safety profile of the BPC-157 + TB-500 combination has not been established in controlled human trials. BPC-157 has limited human exposure data, while FDA’s 2026 TB-500 review found insufficient human-use information to establish clinical safety or effectiveness. Potential interaction or additive effects from administering both compounds together remain unknown.
Reported Adverse Effects
No reliable adverse-event frequency has been established for the combination. Anecdotal reports associated with research-peptide use include injection-site irritation, headache, fatigue, dizziness, and nausea. Product contamination, incorrect concentration, and peptide-related impurities represent additional risks with unregulated preparations.
Contraindications & Cautions
No validated clinical contraindication framework exists for the combination. Particular caution is warranted where stimulation of angiogenesis or cell migration could be undesirable, during pregnancy or breastfeeding, and in populations for whom long-term safety has not been studied. Competitive athletes should also verify current anti-doping rules.
Cancer Considerations
Editorial evidence assessment, not a validated risk score or clearance for use. Unknown risk does not mean low risk; these notes do not establish safety during active cancer or remission.
Cancer Concern Assessment
Elevated concern
Basis for Concern
Both components have demonstrated pro-angiogenic activity in experimental systems. BPC-157 can activate VEGFR2-related angiogenic signaling, while thymosin-beta-4-derived actin-binding sequences promote angiogenesis and cell migration. Because those pathways can also participate in tumor vascularization and progression, the combination creates a meaningful theoretical concern despite the absence of evidence showing that it causes human cancer.
Active Cancer
Caution due to mechanism
There are no controlled studies establishing safety of the combination in people with active malignancy. Its pro-angiogenic and cell-migration mechanisms create a theoretical concern when tumor growth or vascularization is present.
Prior Cancer / Remission
Individualized caution
No evidence-based remission interval has been established for either the combination or its individual components. Prior cancer history does not have sufficient direct research to establish safety or quantify recurrence risk.
Status
Regulatory Status
Neither BPC-157 nor TB-500 is FDA approved for therapeutic use, and the BPC-157 + TB-500 combination has no FDA-approved indication. In July 2026, FDA’s Pharmacy Compounding Advisory Committee considered BPC-157- and TB-500-related bulk drug substances separately for possible inclusion on the 503A Bulks List. The committee recommendation does not constitute FDA approval or establish safety or efficacy.
Development / Research Status
Preclinical research compound
Market Classification
Research-use compound
Status Notes
“Wolverine Stack” is an informal name for combining BPC-157 and TB-500 rather than a distinct pharmaceutical compound or clinical protocol. FDA reviews BPC-157 and TB-500 as separate substances. FDA staff concluded in 2026 that available evidence was insufficient to establish the clinical safety and effectiveness necessary to support the reviewed compounding uses.
Research & Evidence
Evidence Level
Insufficient evidence
Research Last Reviewed
2026-09-05
Research Overview
Evidence supporting the combination is substantially weaker than the evidence for either component individually. Most mechanistic rationale comes from separate BPC-157 and thymosin-beta-4/TB-500-related experiments. Controlled studies comparing the combination with either peptide alone have not established additive or synergistic efficacy.
Human Research
A small retrospective knee-pain report included 16 patients treated with intra-articular BPC-157; four received BPC-157 together with thymosin beta-4. Three of those four reported significant improvement. The uncontrolled design, very small combination subgroup, lack of standardized comparative treatment, and use of thymosin beta-4 rather than clearly characterized TB-500 prevent this study from establishing efficacy or dosing for the Wolverine blend. FDA’s 2026 review of TB-500 separately concluded that human-use information was inadequate to determine clinical safety or effectiveness.
Animal Research
BPC-157 has improved functional, biomechanical, histologic, and structural outcomes in multiple animal models of tendon, ligament, muscle, and bone injury. Separately, thymosin beta-4 and its LKKTETQ actin-binding sequence have promoted dermal wound repair, collagen deposition, cell migration, and angiogenesis in animal models. These findings support biological plausibility for tissue-repair research but do not demonstrate that combining the peptides produces superior outcomes.
In Vitro Research
BPC-157 has demonstrated pro-angiogenic activity through VEGFR2 expression, internalization, and downstream Akt/eNOS signaling in endothelial models. Thymosin beta-4-derived LKKTETQ sequences have demonstrated effects on endothelial migration, vessel sprouting, angiogenesis, and wound-healing pathways. These mechanisms are complementary in theory, but direct experimental evidence establishing synergy between BPC-157 and TB-500 remains limited.